Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith G Warshaw

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of the Pediatric Infectious Diseases Society|March 25, 2017
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and YouthMeredith G Warshaw, George K Siberry, Paige Williams, et al.
Archives of General Psychiatry|May 2, 2002
Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorderAnn O Massion, Ingrid R Dyck, M Tracie Shea, et al.
Plos One|November 23, 2020
Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitorsDwight E Yin, Christina Ludema, Stephen R Cole, et al.
Clinical Trials (London, England)|February 1, 2017
The interaction between equipoise and logistics in clinical trials: A case studyMeredith G Warshaw, Vincent J Carey, Elizabeth J McFarland, et al.
Clinical and Vaccine Immunology : CVI|April 19, 2013
Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youthStephen A Spector, Min Qin, Jorge Lujan-Zilbermann, et al.
The Journal of Pediatrics|May 25, 2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virusJorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescentsGeorge K Siberry, Paige L Williams, Jorge Lujan-Zilbermann, et al.
Plos One|June 13, 2017
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trialAllison L Agwu, Meredith G Warshaw, Elizabeth J McFarland, et al.
Pediatrics|October 1, 2014
Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiationDwight E Yin, Meredith G Warshaw, William C Miller, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of the Pediatric Infectious Diseases Society|March 25, 2017
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and YouthMeredith G Warshaw, George K Siberry, Paige Williams, et al.
Archives of General Psychiatry|May 2, 2002
Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorderAnn O Massion, Ingrid R Dyck, M Tracie Shea, et al.
Plos One|November 23, 2020
Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitorsDwight E Yin, Christina Ludema, Stephen R Cole, et al.
Clinical Trials (London, England)|February 1, 2017
The interaction between equipoise and logistics in clinical trials: A case studyMeredith G Warshaw, Vincent J Carey, Elizabeth J McFarland, et al.
Clinical and Vaccine Immunology : CVI|April 19, 2013
Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youthStephen A Spector, Min Qin, Jorge Lujan-Zilbermann, et al.
The Journal of Pediatrics|May 25, 2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virusJorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescentsGeorge K Siberry, Paige L Williams, Jorge Lujan-Zilbermann, et al.
Plos One|June 13, 2017
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trialAllison L Agwu, Meredith G Warshaw, Elizabeth J McFarland, et al.
Pediatrics|October 1, 2014
Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiationDwight E Yin, Meredith G Warshaw, William C Miller, et al.
Pageof 2